Genome-Wide Association Study Evaluating Lp-PLA2 Mass and Activity at Baseline and Following Rosuvastatin Therapy
نویسندگان
چکیده
Center for Cardiovascular Disease Prevention, the Division of Preventive Medicine, JUPITER Trial Coordinating Center, Division of Genetics, Division of Cardiology, Brigham and Women’s Hospital, Boston, MA; Helmholtz Zentrum München, German Research Center for Environmental Health, Research Unit of Molecular Epidemiology, Neuherberg, Germany; National Heart, Lung, and Blood Institute’s & Boston University's Framingham Heart Study, Framingham; Dept of Biostatistics, Boston University School of Public Health, Boston, MA; Division of Atherosclerosis & Vascular Medicine, Dept of Medicine, Baylor College of Medicine, Methodist DeBaakey Heart and Vascular Center, Houston, TX; Personalised Healthcare & Biomarkers, AstraZeneca Research & Development, Alderley Park, UK; Global Epidemiology, AstraZeneca Research and Development, Mölndal; Unit of Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Harvard Medical School, Boston, MA †contributed equally
منابع مشابه
Genome-wide association study evaluating lipoprotein-associated phospholipase A2 mass and activity at baseline and after rosuvastatin therapy.
BACKGROUND Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is a proinflammatory enzyme bound to low-density lipoprotein cholesterol and other circulating lipoproteins. Two measures of Lp-PLA(2), mass and activity, are associated with increased cardiovascular risk. Data are sparse regarding genetic determinants of Lp-PLA(2) mass and activity, and no prior data are available addressing gene...
متن کاملDifferential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
OBJECTIVE Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a predictor for incident atherosclerotic disease. We investigated the effect of 3 hypolipidemic drugs that exert their action through different mechanisms on plasma and lipoprotein-associated Lp-PLA2 activity and mass. METHODS AND RESULTS In 50 patients with Type IIA dyslipidemia were administered rosuvastatin (10 mg daily), where...
متن کاملComparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction
Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hsCRP), and the addition of ezetimibe to statins further reduces LDL-C and hsCRP. Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a potentially important pathogenic factor participating in the progression of atherosclerosis. The aim of current study was to investigate how the addition of ezet...
متن کاملGenome-Wide Association Study of Lp-PLA2 Activity and Mass in the Framingham Heart Study
Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) is an emerging risk factor and therapeutic target for cardiovascular disease. The activity and mass of this enzyme are heritable traits, but major genetic determinants have not been explored in a systematic, genome-wide fashion. We carried out a genome-wide association study of Lp-PLA(2) activity and mass in 6,668 Caucasian subjects from the...
متن کاملClinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women.
BACKGROUND Findings regarding the association of lipoprotein-associated phospholipase A₂ (Lp-PLA2) activity and mass with incident cardiovascular disease (CVD) have been inconsistent, and their role in risk prediction is uncertain. METHODS A case-cohort sample from the Women's Health Initiative Observational Study (WHI-OS) comprised 1821 CVD cases and a reference subcohort of 1992 women. We u...
متن کامل